Expertise in
2
conditions

Dr. Aleksandra P. Petrovic

Hematology | Oncology
Seattle Children's Hospital
4800 Sand Point Way NE, 
Seattle, WA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
24 Years of Experience
Expertise in
2
conditions
Seattle Children's Hospital
4800 Sand Point Way NE, 
Seattle, WA 

Overview

Aleksandra Petrovic is a Hematologist and an Oncologist practicing medicine in Seattle, Washington. She has been practicing medicine for over 24 years.

Dr. Petrovic is highly rated in 2 conditions, according to our data. Her clinical expertise encompasses Graft Versus Host Disease (GvHD), Primary Immunodeficiency (PID), Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Vitrectomy.

She is actively involved in clinical research, co-authoring 66 peer reviewed articles and participating in 11 clinical trials. Dr. Petrovic is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in FL

Languages Spoken

English
Bosnian
Croatian
Japanese
Serbian

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Community Health
  • EPO
  • HMO
Moda Health
  • EPO
  • PPO
Premera
  • EPO
  • PPO

Locations

Seattle Children's Hospital
4800 Sand Point Way NE, Seattle, WA 98105
Other Locations
Office
1900 9th Ave, Seattle, WA 98101

Additional Areas of Focus

Dr. Petrovic has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units Manufactured by the National Cord Blood Program and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients
A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units Manufactured by the National Cord Blood Program and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients
Enrollment Status: Recruiting
Publish Date: April 13, 2026
Intervention Type: Biological
Study Phase: Phase 2
A Pilot Feasibility Study of Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants Using a Self-Inactivating Lentiviral Vector to Transduce Autologous CD34+ Hematopoietic Cells
A Pilot Feasibility Study of Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants Using a Self-Inactivating Lentiviral Vector to Transduce Autologous CD34+ Hematopoietic Cells
Enrollment Status: Suspended
Publish Date: November 10, 2025
Intervention Type: Device, Genetic, Drug
Study Drugs: Busulfan, Autologous CD34-Positive GammaC-Transduced Lentiviral Bone Marrow Cells
Study Phase: Phase 1/Phase 2
A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) Following Allogeneic Hematopoietic Cell Transplantation (HCT)
A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) Following Allogeneic Hematopoietic Cell Transplantation (HCT)
Enrollment Status: Completed
Publish Date: October 16, 2024
Intervention Type: Drug, Other
Study Phase: Phase 3
Applying Biomarkers to Long-term Effects in Child and Adolescent Cancer Treatment (ABLE Team) - Predictive Biomarkers For Pediatric Chronic Graft-Versus-Host Disease
Applying Biomarkers to Long-term Effects in Child and Adolescent Cancer Treatment (ABLE Team) - Predictive Biomarkers For Pediatric Chronic Graft-Versus-Host Disease
Enrollment Status: Unknown
Publish Date: December 05, 2023
Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies
Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies
Enrollment Status: Unknown
Publish Date: February 08, 2023
An Intermediate-size, Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
An Intermediate-size, Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
Enrollment Status: No_longer_available
Publish Date: March 14, 2022
Intervention Type: Drug
Pediatric Blood & Marrow Transplant Consortium (PBMTC) Phase II Myeloablative Haploidentical BMT With Post-transplantation Cyclophosphamide for Pediatric Patients With Hematologic Malignancies
Pediatric Blood & Marrow Transplant Consortium (PBMTC) Phase II Myeloablative Haploidentical BMT With Post-transplantation Cyclophosphamide for Pediatric Patients With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: November 26, 2021
Intervention Type: Radiation, Other, Drug
Study Phase: Phase 2
Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995
Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995
Enrollment Status: Unknown
Publish Date: September 02, 2021
A Retrospective and Cross-Sectional Analysis of Patients Treated for SCID Since January 1,1968 (RDCRN PIDTC-6902)
A Retrospective and Cross-Sectional Analysis of Patients Treated for SCID Since January 1,1968 (RDCRN PIDTC-6902)
Enrollment Status: Unknown
Publish Date: November 12, 2020
A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children With SCID Disorders (RDCRN PIDTC-6901)
A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children With SCID Disorders (RDCRN PIDTC-6901)
Enrollment Status: Enrolling_by_invitation
Publish Date: November 10, 2020
View 9 Less Clinical Trials

66 Total Publications

Post Hematopoietic Cell Transplantation Maintenance Therapy With Low-Dose Azacitidine in a Pediatric Population With High-Risk Myeloid Malignancies.
Post Hematopoietic Cell Transplantation Maintenance Therapy With Low-Dose Azacitidine in a Pediatric Population With High-Risk Myeloid Malignancies.
Journal: Transplantation and cellular therapy
Published: September 22, 2025
Similar Doctors
Expertise in
22
conditions
Dr. Douglas S. Hawkins
Hematology | Oncology
Expertise in
22
conditions
Dr. Douglas S. Hawkins
Hematology | Oncology
Referral may be required

Seattle Children's Hospital

4800 Sand Point Way NE, 
Seattle, WA 
 (0.1 miles away)
206-987-2000
Languages Spoken:
English, German
See accepted insurances
Accepting New Patients
Offers Telehealth

Douglas Hawkins is a Hematologist and an Oncologist practicing medicine in Seattle, Washington. Dr. Hawkins is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Rhabdomyosarcoma, Adult Soft Tissue Sarcoma, Osteosarcoma, Osteotomy, and Bone Marrow Aspiration. Dr. Hawkins is currently accepting new patients.

Expertise in
24
conditions
Dr. Sarah S. Leary
Hematology | Oncology
Expertise in
24
conditions
Dr. Sarah S. Leary
Hematology | Oncology
Referral may be required

Seattle Children's Hospital

4800 Sand Point Way NE, 
Seattle, WA 
 (0.1 miles away)
206-987-2106
Languages Spoken:
English, Castilian, French, Hindi, Mandarin, Punjabi, Spanish, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Sarah Leary is a Hematologist and an Oncologist practicing medicine in Seattle, Washington. Dr. Leary is highly rated in 24 conditions, according to our data. Her clinical expertise encompasses Medulloblastoma, Glioma, Gliomatosis Cerebri, Brain Tumor, and Bone Marrow Aspiration. Dr. Leary is currently accepting new patients.

Expertise in
11
conditions
Dr. James M. Olson
Hematology | Oncology
Expertise in
11
conditions
Dr. James M. Olson
Hematology | Oncology
Referral may be required

Seattle Children's Hospital

4800 Sand Point Way NE, 
Seattle, WA 
 (0.1 miles away)
206-987-2106
Languages Spoken:
English, Afrikaans, Korean, Russian
See accepted insurances
Accepting New Patients
Offers Telehealth

James Olson is a Hematologist and an Oncologist practicing medicine in Seattle, Washington. Dr. Olson is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Medulloblastoma, Embryonal Tumor with Multilayered Rosettes, Posterior Fossa Tumor, and Glioma. Dr. Olson is currently accepting new patients.

Frequently Asked Questions about Dr. Aleksandra P. Petrovic

How do I make an appointment with Dr. Aleksandra P. Petrovic?

You can book an appointment with Dr. Aleksandra P. Petrovic by calling their office at 206-987-2106. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Aleksandra P. Petrovic a top-rated expert for Graft Versus Host Disease (GvHD)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Aleksandra P. Petrovic is classified as an Advanced expert for Graft Versus Host Disease (GvHD), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Aleksandra P. Petrovic specialize in?

While Dr. Aleksandra P. Petrovic is a Hematology, they have specific expertise in Graft Versus Host Disease (GvHD), Primary Immunodeficiency (PID), and Bone Marrow Transplant. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Aleksandra P. Petrovic participate in research or clinical trials?

Yes. Dr. Aleksandra P. Petrovic has published 66 articles and abstracts on conditions like Graft Versus Host Disease (GvHD). You can view a list of Dr. Aleksandra P. Petrovic's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Aleksandra P. Petrovic accept my insurance?

Dr. Aleksandra P. Petrovic accepts most major insurance plans, including Community Health and Moda Health. We recommend calling the office directly at 206-987-2106 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Petrovic's expertise for a condition
ConditionClose
      View All 15 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile